▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1331 by analyst upside · 2026-06-27
ALMS
Alumis Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+51.9%
implied upside to consensus target
Current Price $26.4
Consensus Target $40.1
Bull Target $55.0
Bear Target $25.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
9
Hold
0
Sell
0
52-Week Low $2.92
52-Week High $30.6
YTD Return +194.8%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E -8.9x
EPS (TTM) $-1.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $8M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.92
52-Week High $30.6
Current Price $26.4
Bear Target $25.0
Bull Target $55.0
● Now $26.4 ● Target $40.1
TRADING DATA
Avg Volume 1.3M
YTD Return +194.8%
Analyst Count 10
Consensus Buy
Upside to Target +51.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Alumis Inc. (ALMS) is currently trading at $26.4 with a Wall Street consensus price target of $40.1, implying potential upside of 51.9% over the next 12 months. 10 analysts currently cover ALMS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $55.0, while the most cautious has a target of $25.0.

ALMS operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 194.8% year-to-date and is currently trading near the upper end of its 52-week range of $2.92 – $30.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy
WAY +70.0%
Waystar Holding Corp.
$4B · P/E 29.7x · Buy
DOCS +21.7%
Doximity, Inc.
$4B · P/E 20.3x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
GRFS +47.0%
Grifols, S.A.
$5B · P/E 10.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ALMS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-05-19 33% win rate (6 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-15 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-15 62% win rate (8 calls)
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-05-15 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-30 14% win rate (7 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-03-30 33% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-30 31% win rate (48 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-03-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →